Drug Profile
Fluticasone/theophylline - Vectura
Alternative Names: ADC 4022/fluticasone; SKP 2075; Theophylline/fluticasone - VecturaLatest Information Update: 28 Sep 2018
Price :
$50
*
At a glance
- Originator Pulmagen Therapeutics
- Developer Vectura
- Class Anti-inflammatories; Antiasthmatics; Antibronchitics; Bronchodilators; Corticosteroids; Xanthines
- Mechanism of Action Glucocorticoid receptor agonists; Histone deacetylase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 28 Sep 2018 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in Switzerland (Inhalation, Powder)
- 13 Aug 2014 Skyepharma acquires fluticasone/theophylline from Pulmagen Therapeutics
- 13 Aug 2014 Preclinical trials in Chronic obstructive pulmonary disease in Switzerland (Inhalation)